CSMG Technologies Live Tissue Connect Subsidiary Completes Duct and Vessel Sealer Prototype.

Expects to File For U.S. and European Marketing Early 2007

CORPUS CHRISTI, Texas -- CSMG Technologies, Inc., (OTCBB: CTUM), a technology management company focused on commercializing human live tissue bonding devices and renewable energy landfill gas production systems, announced that its Live Tissue Connect ("LTC") technology subsidiary has completed its duct and vessel sealer prototype. This is the first specific procedure device of some 13 specific procedure devices LTC has identified from over 80 procedures performed by the technology's universal device used in Ukraine. LTC will begin the second prototype specific procedure device for end-to-end, end-to-side and side-to-side anastomosis (reconnection) of intestines which should be completed in about four months.

LTC expects to complete a U.S. and European regulatory device meeting FDA and European CE Mark standards, respectively, and file with the two entities early next year.

"The challenge was to isolate the duct and vessel sealing capabilities of the technology from other procedures on the universal device, make the procedure automatic so that once the surgeon grasps the tissue and activates the energy switch the automatic control system takes over and completes a consistently reliable leak proof seal without charring. We used the automatic control procedure in more than 120 bursts strength tests of vessels between 3.5 to 14 mm in diameter and averaged 1,030 mm Hg burst strength. The significance of the automatic controlled system is we are able to achieve the same burst strength on 14 mm diameter vessels as we were on 3.5 mm diameter vessels. To our knowledge it has been problematic for our competitors to achieve consistently reliable burst strength on vessels over 9-10 mm in diameter. We are excited about licensing or bringing this product to market," said Donald Robbins, president and CEO of CSMG Technologies.

About CSMG Technologies' Tissue Welding/Bonding Technology

Surgeons at 27 Ukraine hospitals and clinics are using the tissue welding/bonding technology in clinical trials. They have completed more than 6,000 human surgeries using more than 80 types of open and laparoscopic surgical procedures, demonstrating the technology is universal in its ability to repair soft biological tissue. These surgeries included lung, neuro-surgery, nasal septum, intestine, stomach, skin, gall bladder, liver, spleen, blood vessels, nerves, alba linea, uterus, bladder, gynecological, fallopian tube, ovary and testicles and dura-matter. Cosmetic surgeries conducted with this technology include breast reduction, breast implants, mastopexy and abdominal plasty. The procedure involves little or no scarring, while restoring the normal function of the body organ or tissue.

The LTC tissue bonding / welding device is a platform technology that bonds and reconnects living soft biological tissue through fusion without the use of foreign matters or conventional wound closing devices such as sutures, staples, sealant, or glues.

The technology was invented and developed at the internationally renowned E.O. Paton Institute of Electric Welding, National Academy of Sciences of Ukraine, Kiev, Ukraine, headed by Professor B.E. Paton. U.S. and Australia patents have been issued, a patent in the European Union has been approved, and additional U.S. and foreign patents are pending.

About CSMG Technologies, Inc.

CSMG Technologies is a technology management company that finances, owns, develops, licenses and markets innovative advanced technologies and business opportunities created in the Ukraine through a network of scientific institutes and private organizations. CSMG has three subsidiaries, Live Tissue Connect, Inc., CSMG Gastech, LLC and Anaerobic Farm Waste, Inc.

For further information on CSMG Technologies and its various subsidiaries, please visit our website at www.ctum.com.

This press release may contain forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934 as amended (the Exchange Act), including all statements that are not statements of historical fact regarding the intent, belief or current expectations of the company, its directors or its officers with respect to, among other things: (i) the company's financing plans; (ii) trends affecting the company's financial condition or results of operations; (iii) the company's growth strategy and operating strategy; and (iv) the declaration and payment of dividends. The words "may," "would," "will," "expect," "estimate," "anticipate," "believe," "intend" and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the company's ability to control, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors.